Evidence map›Paper›PMID 36769745›Full record

ReviewJournal of clinical medicine2023

Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy.

Tiantian Zhang, Tony Hong-Ting Jou, Jerline Hsin, Zhe Wang, Kelly Huang, Jian Ye, Holly Yin, Yan Xing

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tiantian ZhangToni Stephenson Lymphoma Center, Department of Hematology and Hematopoietic Stem Cell Transplantation, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.
Tony Hong-Ting JouSchool of Medicine, National Yang Ming Chiao Tung University, Taipei 11217, Taiwan.
Jerline HsinDepartment of Pharmacy, City of Hope, Duarte, CA 91010, USA.
Zhe WangHigh Throughput Screening Core, Department of Share Resources, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.
Kelly HuangDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA.
Jian YeDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.
Holly YinHigh Throughput Screening Core, Department of Share Resources, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.
Yan XingDepartment of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA 91010, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The landscape of melanoma treatment has undergone a dramatic revolution in the past decade. The use of oncolytic viruses (OVs) represents a novel therapeutic approach that can selectively infect and lyse tumor cells and induce local and systemic antitumor immune responses. As the first OV approved by the Food and Drug Administration (FDA) for melanoma treatment, talimogene laherparepvec (T-VEC), a genetically modified herpes simplex virus (HSV), has shown promising therapeutic effects in the treatment of advanced melanoma, both as a monotherapy or in combination with other immunotherapies, such as the immune checkpoint inhibitors (ICIs). With proven efficacy, T-VEC has been evaluated against a variety of other cancer types in a clinical trial setting. In this article, we will provide a review on OVs and the application of T-VEC in melanoma monotherapy and combination therapy. In addition, we will review the recent progress of T-VEC application in other cutaneous cancer types. Moreover, we will briefly describe our experience of T-VEC therapy at City of Hope, aiming to provide more insight for expanding its future application.

Indexed as

clinical trialscombinational therapycutaneous cancersimmune checkpoint inhibitorsimmunotherapymelanomaoncolytic virotherapytargeted therapyT-VEC

Identifiers

PMID36769745
PMCPMC9917711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.